Loading...
•
Mar 31, 2022
Pulmonx Q1 2022 Earnings Report
Pulmonx's first quarter performance benefited from a strong recovery in procedure volumes and account activity.
Key Takeaways
Pulmonx reported a 17% increase in worldwide revenue, reaching $10.8 million in Q1 2022, with a gross margin of 75%. The company added 16 new U.S. treatment centers, increasing the total to 230.
Worldwide revenue increased by 17% to $10.8 million compared to the same period last year, and 20% on a constant currency basis.
Gross margin improved to 75% in the first quarter of 2022, up from 72% in the same period last year.
U.S. revenue grew by 40% compared to the first quarter of 2021.
16 new U.S. treatment centers for Zephyr Valves were added in Q1 2022, bringing the total to 230.
Revenue by Geographic Location
Forward Guidance
Pulmonx continues to expect revenue for the full year 2022 to be in the range of $55 million to $60 million. The Company also continues to expect total operating expenses for the full year 2022 to fall within the range of $100 million to $105 million inclusive of stock-based compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...